Home » Stocks » ITRM

Iterum Therapeutics PLC (ITRM)

Stock Price: $0.631 USD -0.500 (-44.20%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
After-hours: $0.625 -0.006 (-0.87%) Jul 26, 5:59 PM
Market Cap 202.43M
Revenue (ttm) n/a
Net Income (ttm) -134.83M
Shares Out 179.14M
EPS (ttm) -2.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $0.631
Previous Close $1.130
Change ($) -0.500
Change (%) -44.20%
Day's Open 0.680
Day's Range 0.630 - 0.779
Day's Volume 59,371,474
52-Week Range 0.451 - 3.000

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DUBLIN, Ireland and CHICAGO, July 26, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral ...

11 hours ago - GlobeNewsWire

Penny Stocks Continue to Heat Up As Summer 2021 Rolls On; Here's 3 to Watch The post Top Penny Stocks to Buy Next Week? 3 to Watch In Summer 2021 appeared first on Penny Stocks to Buy, Picks, News and I...

Other stocks mentioned: GOED, GSAT
1 week ago - PennyStocks

Looking for the best penny stocks to buy in 2021? Check these 7 out for your watchlist The post Are These Hot Penny Stocks Worth Buying Right Now?

Other stocks mentioned: RSLS, VERB
2 weeks ago - PennyStocks

NEW YORK, July 7, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Iterum Therapeutics plc ("Iterum" or the "Company") (NASDAQ: ITRM). Such investors are advised to c...

2 weeks ago - PRNewsWire

Which Reddit penny stocks are investors watching right now? Check these 7 out The post Trending Reddit Penny Stocks to Buy Now?

Other stocks mentioned: CEI, ENZC, HUT, IDEX, KOS, ZOM
2 weeks ago - PennyStocks

A lack of clarity and final decision in the U.S. Food and Drug Administration's (FDA) recent letter to Iterum Therapeutics PLC (NASDAQ:ITRM) failed to deter H.C. Wainwright & Co's bullish sentiment on I...

3 weeks ago - Benzinga

The company received disappointing news from the FDA.

3 weeks ago - The Motley Fool

DUBLIN, Ireland and CHICAGO, July 01, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral ...

3 weeks ago - GlobeNewsWire

Looking for penny stocks to buy in July 2021? Here's 7 for your watchlist The post Top Penny Stocks to Buy in July?

Other stocks mentioned: AIHS, ASXC, BEST, CYRN, IQST, RIGL
4 weeks ago - PennyStocks

Which penny stocks are investors watching as June comes to an end? The post 8 Penny Stocks to Watch Right Now As June Comes to an End appeared first on Penny Stocks to Buy, Picks, News and Information |...

Other stocks mentioned: ANY, CBIO, JOB, SEAC, SOLO, VISL, VTGN
4 weeks ago - PennyStocks

Are these 9 penny stocks on your Summer watchlist right now? The post Top 9 Penny Stocks With High Volume to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...

Other stocks mentioned: BBIG, GSAT, HMBL, MUX
1 month ago - PennyStocks

Looking for well-funded biotech penny stocks? Check these 3 small-caps out The post Best Biotech Penny Stocks to Buy?

Other stocks mentioned: APRE, POAI
1 month ago - PennyStocks

AMC stock surge triggers momentum for 3 Reddit penny stocks The post Best Penny Stocks To Buy Now? 3 Reddit Stocks To Watch After AMC Pop appeared first on Penny Stocks to Buy, Picks, News and Informati...

Other stocks mentioned: ARC, OEG
1 month ago - PennyStocks

With biotech penny stocks back in focus, which small-caps are you watching? The post Hot Biotech Penny Stocks To Buy?

Other stocks mentioned: EVFM, TTOO
1 month ago - PennyStocks

The FDA gave the company some good news.

1 month ago - The Motley Fool

Iterum Therapeutics plc (NASDAQ: ITRM) has concluded a late-cycle meeting with the FDA related to its application for sulopenem etzadroxil/probenecid. Sulopenem is under review as a treatment for uncomp...

1 month ago - Benzinga

DUBLIN, Ireland and CHICAGO, May 27, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral a...

1 month ago - GlobeNewsWire

Analysts say these are penny stocks to buy right now & have bullish targets to back it up. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now appeared first on Penny Stocks to...

Other stocks mentioned: MRKR, SESN, TELL, VTGN
2 months ago - PennyStocks

Looking for Reddit penny stocks to buy? Check these 3 out for some watchlist inspiration The post 3 Reddit Penny Stocks to Watch That You May Have Missed Last Week appeared first on Penny Stocks to Buy,...

Other stocks mentioned: PRPO, VTNR
2 months ago - PennyStocks

FDA Review of NDA for Oral Sulopenem Continues; Current Prescription Drug User Fee Act (PDUFA) date of July 25, 2021

2 months ago - GlobeNewsWire

DUBLIN, Ireland and CHICAGO, May 07, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and...

2 months ago - GlobeNewsWire

Biotech penny stocks continue to see momentum; should you add these 3 to your watchlist? The post Top Biotech Penny Stocks to Buy?

Other stocks mentioned: ASXC, ONTX, ZOM
3 months ago - PennyStocks

Biotech penny stocks are all the rage; should you check these four out? The post 4 Biotech Penny Stocks To Watch That Are Heating Up This Month appeared first on Penny Stocks to Buy, Picks, News and Inf...

Other stocks mentioned: AIKI, OVID, TTOO
3 months ago - PennyStocks

Iterum Therapeutics plc (NASDAQ: ITRM) shares dropped after the company in an SEC filing disclosed that the FDA needs additional time to review its sulopenem application.  The application seeks approval...

3 months ago - Benzinga

DUBLIN, Ireland and CHICAGO, April 06, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral a...

3 months ago - GlobeNewsWire

Immutep Limited (IMMP) stock is soaring higher on Thursday despite a lack of recent news coming from the company but there is a reason why. The post IMMP Stock: Why Is Biotech Company Immutep Rocketing ...

Other stocks mentioned: BMY, CLVS, GSK, IMMP, NNVC, NVS
4 months ago - InvestorPlace

The fact that other antibiotic makers have declared bankruptcy in recent years is a negative sign for Iterum. Long-term investors should avoid ITRM stock.

4 months ago - InvestorPlace

Fundamentally, ITRM stock is an excellent play on multi-drug resistance pathogen solutions but you must also be aware of its extreme boom-bust cycles. The post Iterum Therapeutics' Science Won't Prevent...

4 months ago - InvestorPlace

Patrick Heron to leave the Board

4 months ago - GlobeNewsWire

- -NDA for Oral Sulopenem has PDUFA date of July 25, 2021 --   - -Cash Runway into First Half of 2023 —

4 months ago - GlobeNewsWire

DUBLIN, Ireland and CHICAGO, March 05, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral a...

4 months ago - GlobeNewsWire

It's encouraging that Iterum's oral antibiotic has blockbuster status potential, but the basic earnings data on ITRM stock signal caution. The post Unfavorable Earnings Profile Doesn't Bode Well for Ite...

4 months ago - InvestorPlace

DUBLIN, Ireland and CHICAGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral an...

5 months ago - GlobeNewsWire

DUBLIN, Ireland and CHICAGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral an...

5 months ago - GlobeNewsWire

DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral an...

5 months ago - GlobeNewsWire

Iterum Therapeutics (ITRM) stock is taking off on Tuesday with heavy trading even without any news coming from the company. The post ITRM Stock: 7 Things for Investors to Know About Iterum Therapeutics ...

5 months ago - InvestorPlace

DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral an...

5 months ago - GlobeNewsWire

DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral an...

5 months ago - GlobeNewsWire

DUBLIN, Ireland and CHICAGO, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral an...

5 months ago - GlobeNewsWire

-- If approved, First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years -- -- PDUFA goal date of July 25, 2021 --

6 months ago - GlobeNewsWire

DUBLIN, Ireland and CHICAGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral an...

6 months ago - GlobeNewsWire

--Dr. Dunne resigns as Chief Scientific Officer-- -- Steven Aronin, M.D., Senior Vice President and Head of Clinical Development, to lead Development and Regulatory Activities --

7 months ago - GlobeNewsWire

Trading on Nasdaq Capital Market is expected to begin on December 23, 2020 Trading on Nasdaq Capital Market is expected to begin on December 23, 2020

7 months ago - GlobeNewsWire

Bilayer tablet patent application could provide U.S. patent coverage for Iterum's commercial formulation through 2039, if granted Bilayer tablet patent application could provide U.S. patent coverage for...

7 months ago - GlobeNewsWire

Iterum Therapeutics (ITRM) is in the news Thursday following news of massive stakes in the company pushing ITRM stock higher. The post Iterum Therapeutics News: Why ITRM Stock Is Rocketing Higher Today ...

7 months ago - InvestorPlace

-- F irst O ral Penem in the U . S . and First New Oral Treatment for uUTI s in Over 20 Years , if approved - - - - Potential Approval Q3 2021 with Priority Review --

7 months ago - GlobeNewsWire

NDA Filing Expected Q4 2020 NDA Filing Expected Q4 2020

8 months ago - GlobeNewsWire

DUBLIN, Ireland and CHICAGO, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibioti...

9 months ago - GlobeNewsWire

Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies

9 months ago - GlobeNewsWire

Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies

9 months ago - GlobeNewsWire

About ITRM

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.

Industry
Biotechnology
IPO Date
May 25, 2018
Stock Exchange
NASDAQ
Ticker Symbol
ITRM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ITRM stock is "Sell." The 12-month stock price forecast is 2.25, which is an increase of 256.86% from the latest price.

Price Target
$2.25
(256.86% upside)
Analyst Consensus: Sell